Salarius Pharmaceuticals (SLRX) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free SLRX Stock Alerts $0.47 +0.01 (+2.17%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 12:08 AM | investorplace.comSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024May 11, 2024 | americanbankingnews.comSalarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Significant Decrease in Short InterestApril 2, 2024 | finance.yahoo.comSLRX Pursues Important GoalMarch 27, 2024 | msn.comWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation DataMarch 25, 2024 | msn.comWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketMarch 23, 2024 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 22, 2024 | sfgate.comSalarius: Q4 Earnings SnapshotMarch 22, 2024 | globenewswire.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | msn.comQuoin stock craters 47% on public offering after rallying in prior sessionMarch 4, 2024 | msn.comQuoin stock soars 60% on FDA update for ichthyosis drugFebruary 22, 2024 | markets.businessinsider.comSalarius Pharmaceuticals Implements Cost-savings MeasuresFebruary 22, 2024 | msn.comSalarius's CEO David Arthur steps downFebruary 22, 2024 | finance.yahoo.comSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesFebruary 9, 2024 | uk.investing.comSalarius Pharmaceuticals Inc (SLRX)January 16, 2024 | finance.yahoo.comSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersJanuary 13, 2024 | wsj.comSquare Pharmaceuticals Ltd.January 3, 2024 | finance.yahoo.comInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNovember 10, 2023 | finance.yahoo.comSLRX Continues Work as it Seeks AlternativesNovember 8, 2023 | morningstar.comSalarius Pharmaceuticals Inc SLRXNovember 7, 2023 | finance.yahoo.comSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramAugust 10, 2023 | bizjournals.comSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsAugust 10, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 9, 2023 | finance.yahoo.comSLRX Pursuing Strategic AlternativesAugust 8, 2023 | marketbeat.comTrading was temporarily halted for "SLRX" at 04:08 PM with a stated reason of "News pending."July 11, 2023 | benzinga.comWatching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price TargetJuly 11, 2023 | finance.yahoo.comSLRX Continues Cancer Fight with Phase I Trial ApprovalJuly 11, 2023 | marketwatch.comSalarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug ApplicationJuly 11, 2023 | finance.yahoo.comSalarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsJune 12, 2023 | finance.yahoo.comSalarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid CongressMay 17, 2023 | marketwatch.comSalarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesMay 16, 2023 | finance.yahoo.comSalarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesMay 12, 2023 | finance.yahoo.comSalarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesMay 11, 2023 | msn.comRecap: Salarius Pharmaceuticals Q1 EarningsMay 11, 2023 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 11, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 9, 2023 | msn.comSalarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhoodMay 9, 2023 | finance.yahoo.comFDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing SarcomaMay 2, 2023 | uk.finance.yahoo.comSalarius Pharmaceuticals, Inc. (SLRX)May 1, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164April 24, 2023 | msn.comSalarius Pharmaceuticals (FRA:FP1) Price Target Decreased by 7.80% to 55.93April 20, 2023 | finance.yahoo.comSalarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual MeetingApril 4, 2023 | finance.yahoo.comSalarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational ConferenceApril 4, 2023 | finance.yahoo.comDiamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023March 27, 2023 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 27, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 15, 2023 | finance.yahoo.comSalarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual MeetingMarch 7, 2023 | finance.yahoo.comSalarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone SymposiaFebruary 16, 2023 | finance.yahoo.comSalarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of TexasJanuary 27, 2023 | finance.yahoo.comSalarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development SummitJanuary 22, 2023 | morningstar.comThinking about buying stock in Salarius Pharmaceuticals, Appharvest, Ally Financial, Jaguar Health, or IONQ? Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent Alert: Is the U.S. Implementing a Digital Dollar? (Ad)Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource in navigating this uncertain terrain. Inside, you'll find expert insights, strategies, and actionable steps to shield your wealth from the impending digital dollar storm. Limited time offer! Claim your guide today and stay ahead of the digital dollar revolution. SLRX Media Mentions By Week SLRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRX News Sentiment▼1.170.54▲Average Medical News Sentiment SLRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRX Articles This Week▼50▲SLRX Articles Average Week Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNOA News Today CYTO News Today ATXI News Today NTBL News Today DRMA News Today ONCO News Today CMND News Today CNSP News Today SXTP News Today AGRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldWhy Is Gold On a MASSIVE rally? Huge AlertsUrgent Alert: Is the U.S. Implementing a Digital Dollar?Gold Gate Capital348 million Americans lives to END as we know it?The Oxford ClubBiden Nomination CANCELED?The Freeport SocietyGold Set to EXPLODE!Gold Safe ExchangeDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
